Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA. Sarashina A, et al. Among authors: woerle hj. Clin Ther. 2010 Jun;32(6):1188-204. doi: 10.1016/j.clinthera.2010.06.004. Clin Ther. 2010. PMID: 20637971 Clinical Trial.
Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects.
Sarashina A, Koiwai K, Seman LJ, Yamamura N, Taniguchi A, Negishi T, Sesoko S, Woerle HJ, Dugi KA. Sarashina A, et al. Among authors: woerle hj. Drug Metab Pharmacokinet. 2013;28(3):213-9. doi: 10.2133/dmpk.dmpk-12-rg-082. Epub 2012 Nov 13. Drug Metab Pharmacokinet. 2013. PMID: 23149871 Free article. Clinical Trial.
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Sarashina A, Ueki K, Sasaki T, Tanaka Y, Koiwai K, Sakamoto W, Woerle HJ, Salsali A, Broedl UC, Macha S. Sarashina A, et al. Among authors: woerle hj. Clin Ther. 2014 Nov 1;36(11):1606-15. doi: 10.1016/j.clinthera.2014.08.001. Epub 2014 Sep 5. Clin Ther. 2014. PMID: 25199997
Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Horie Y, Sarashina A, Gong Y, von Eynatten M, Woerle HJ, Dugi KA. Kawamori R, et al. Among authors: woerle hj. Diabetes Obes Metab. 2012 Apr;14(4):348-57. doi: 10.1111/j.1463-1326.2011.01545.x. Epub 2012 Jan 17. Diabetes Obes Metab. 2012. PMID: 22145698 Clinical Trial.
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y, Kanada S, Watada H, Sarashina A, Taniguchi A, Hayashi N, Graefe-Mody EU, Woerle HJ, Dugi KA. Horie Y, et al. Among authors: woerle hj. Clin Ther. 2011 Jul;33(7):973-89. doi: 10.1016/j.clinthera.2011.06.005. Epub 2011 Jul 2. Clin Ther. 2011. PMID: 21723606 Clinical Trial.
192 results